The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has led to a global health crisis, emphasizing the urgent need for effective vaccines. While several vaccines have been developed and are being administered worldwide, there is ongoing research to improve their efficacy and delivery methods. One promising approach is the development of a new formulation for the transmission of mRNA vaccines to the nasal mucosa, which could enhance mucosal immunity and provide additional protection against SARS-CoV-2. This article describes the design and potential benefits of such a formulation.
HTML PDFShare this article
Journal of Bioprocessing & Biotechniques received 3351 citations as per Google Scholar report
